News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 233
- Sources here
- 26
- Companies here
- 7
Search results
Stored financial headlines
Active search
233 matching headlines
Ticker or company: MYEMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
AstraZeneca held talks with Bristol-Myers through spring, summer - FT
AstraZeneca reportedly engaged in discussions with Bristol-Myers Squibb over the spring and summer regarding a potential acquisition. The talks were centered around AstraZeneca purchasing Bristol-Myers in a mostly stock-based deal at a premium.
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
Everything You Need to Know About the AstraZeneca–Bristol Myers Squibb Merger Rumors
Reports recently surfaced regarding a potential merger between pharmaceutical giants AstraZeneca and Bristol Myers Squibb, causing significant industry speculation. Although a senior source reportedly debunked these rumors, the prospect of such a large-scale merger between two strong performers raised questions about its strategic rationale …
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
News | Bristol Myers Squibb plans $2.3 billion Houston campus
Bristol Myers Squibb announced plans for a $2.3 billion, 600,000-square-foot campus in Houston's Generation Park, expected to create nearly 500 skilled jobs by 2030. This investment is part of a larger $40 billion commitment to U.S. operations, aiming to boost domestic manufacturing and reduce …
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
Bristol Myers Squibb lays out plan for $2.3B manufacturing facility in Houston
Bristol Myers Squibb has announced a $2.3 billion investment to build a manufacturing campus in Houston, significantly increasing its initial estimate of $1 billion. The facility, expected to employ nearly 500 people and be completed by 2030, will produce small molecules, biologics, and antibody-drug …
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
BMS Chooses Houston for $2.3B Manufacturing Facility
Bristol Myers Squibb (BMS) has selected Houston as the location for a new $2.3 billion multi-modal manufacturing campus. This facility, part of BMS's $40 billion U.S. investment, will support the production of various treatments including small molecules, biologics, and ADCs. The campus aims to …
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
Pharma giant bets $2.3B on massive new Houston campus
Bristol Myers Squibb has chosen Houston for a new $2.3 billion manufacturing campus at Generation Park. This massive 600,000-square-foot facility is expected to create nearly 500 skilled jobs and approximately 2,000 indirect jobs during its construction phase. The investment is part of the company's …
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
New Bristol Myers Squibb facility coming to Generation Park
Global biopharmaceutical company Bristol Myers Squibb is set to establish a new pharmaceutical manufacturing campus in the Houston area, specifically near Generation Park. FOX 26's Karys Belger reported on this development. The facility will mark a significant expansion for the company in the region.
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
Bristol Myers Squibb to expand in Harris County
The article states that Bristol Myers Squibb plans to expand its operations in Harris County. No further details are provided regarding the nature or scope of this expansion.
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
Pharmaceutical giant to build $2.3B plant, create 500 jobs in Texas
Bristol Myers Squibb is investing $2.3 billion to construct a new drug manufacturing campus in Houston, Texas, creating nearly 500 initial jobs and 2,000 construction jobs. The 600,000-square-foot facility at Generation Park will produce various next-generation medicines. Texas Governor Greg Abbott praised the investment, …
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
Bristol Myers Squibb to build $2.3 billion Houston campus
Bristol Myers Squibb announced Monday it will build a $2.3 billion drug manufacturing campus in Houston, Texas, part of the company's broader $40 billion commitment to invest in the United States over five years. The roughly 600,000-square-foot campus will be located at Generation Park, …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Bristol Myers Squibb selects Generation Park for new $2.3B manufacturing campus
Bristol Myers Squibb has chosen Generation Park in northeast Houston for its new $2.3 billion manufacturing campus, a project anticipated to create nearly 500 jobs directly and 2,000 construction jobs. The 600,000-square-foot facility will produce various medicines, supporting the company's $40 billion investment in …
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
Bristol Myers Squibb opening pharmaceutical manufacturing campus near Houston
Bristol Myers Squibb is establishing a new $2.3 billion pharmaceutical manufacturing campus in Generation Park near Houston, expected to create nearly 500 new permanent jobs and 2,000 construction jobs. This marks the second major pharmaceutical investment in the area, following Eli Lilly's plans for …
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
Bristol Myers To Invest $2.3 Bln In Houston Manufacturing Campus; To Create 500 Skilled Jobs
(RTTNews) - Bristol Myers Squibb (BMY) announced Monday an investment of approximately $2.3 billion in the U.S., while selecting Houston, Texas, as the site for a new, state-of-the-art multi-modal manufacturing campus to accelerate the delivery of next-generation medicines to patients. The approximately 600,000 square …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Bristol Myers to build $2.3 billion manufacturing site in Houston
Bristol Myers Squibb announced a $2.3 billion investment to construct a new manufacturing facility in Houston, Texas, creating nearly 500 skilled jobs and approximately 2,000 construction jobs. This initiative is part of the company's $40 billion commitment to U.S. investments and aligns with a …
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
New State-of-the-Art Facility Will Create Nearly 500 Skilled Jobs and Accelerate the Delivery of Next-Generation Medicines Investment Furthers BMS' $40 Billion Commitment to American Innovation, Manufacturing and Economic Growth PRINCETON, N.J., August 10, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced the selection of Houston, …
Sharemaestro market context Trend signal active 52 weeks +19.5%Weekly Recap: Merger talks with Bristol Myers and Imjudo launch in China
AstraZeneca (AZN) has been involved in preliminary merger discussions with Bristol Myers Squibb, which reportedly led to a dip in AZN's share price. Concurrently, AstraZeneca is focusing on organic growth, marked by the launch of its cancer drug Imjudo in China, a new biologics …
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
Bristol Myers Squibb Invests $2.3B in New Houston Pharma Facility
Bristol Myers Squibb is investing $2.3 billion to construct a 600,000-square-foot manufacturing facility at Generation Park in northeast Houston, expected to create nearly 500 jobs. This significant investment further establishes Houston as a leading hub for life sciences and advanced manufacturing, following similar large-scale …
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
Oliver Luxxe Assets LLC Has $2.39 Million Holdings in Myers Industries, Inc. $MYE
Oliver Luxxe Assets LLC significantly reduced its stake in Myers Industries (NYSE:MYE) by 37.9% in the second quarter, now holding 67,799 shares valued at $2.39 million. Despite this reduction, Myers Industries reported strong quarterly results, exceeding analyst expectations with $0.53 EPS and $179.2 million …
MYE
main company
Sharemaestro market context
Trend signal active
52 weeks +104.3% · Next-week setup positive 58.3%
What the AstraZeneca-BMS rumors reveal about pharma megamergers
Reports of a potential megamerger between AstraZeneca and Bristol Myers Squibb, which would have created a $400 billion pharmaceutical giant, were quickly disputed. While AstraZeneca's strong pipeline makes a merger less appealing for them, Bristol Myers Squibb could benefit due to impending patent expirations …
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
Beyond the Megamerger: How Rumored AstraZeneca–BMS Discussions Signal a New Era of Pharmaceutical Competition
Rumors of a potential AstraZeneca-Bristol Myers Squibb merger, despite being disputed, highlight a fundamental shift in pharmaceutical competition. The article suggests that future success in the industry will depend not just on scientific innovation, but on integrated capabilities including AI, resilient manufacturing, and diversified …
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
CPI | AstraZeneca, Bristol Myers Dismiss Merger Talk Speculation
AstraZeneca Plc and Bristol Myers Squibb Co. have dismissed speculation regarding a potential merger, stating they are not engaged in such discussions. This clarification came after an earlier report by the Financial Times suggested talks were underway for a $400 billion deal, which caused …
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%
Myers Industries Announces 2026 Second Quarter Results
Myers Industries Inc. (NYSE: MYE) announced its second-quarter 2026 results, highlighting outstanding revenue growth and expanded profitability driven by its Focused Transformation initiatives. The company reported a 13% increase in net sales, strong cash flow generation, and significant improvements in its balance sheet and …
MYE
main company
Sharemaestro market context
Trend signal active
52 weeks +104.3% · Next-week setup positive 58.3%
Senior Source Denies AstraZeneca and Bristol Myers Deal Talks : Report
A senior source has denied any ongoing or historical discussions between AstraZeneca and Bristol Myers Squibb regarding a potential merger, contradicting earlier speculation about a nearly $400 billion deal. The denial follows initial reports that caused AstraZeneca's shares to drop, with the subsequent denial …
BMY
main company
Sharemaestro market context
Trend signal active
52 weeks +38.1%